Company Overview - Humana is a prominent player in the healthcare industry, providing a range of health insurance products and services, particularly known for its Medicare plans [1] - The company has a significant presence in the U.S. healthcare market and competes with major insurers like UnitedHealth Group and Anthem [1] Stock Performance - Humana's current stock price is $260.28, reflecting an increase of $2.12 or 0.82% [4] - The stock has fluctuated between a low of $256.35 and a high of $266.08 during the trading day, with a yearly range from a high of $315.35 to a low of $206.87 [4] Market Capitalization and Trading Volume - Humana's market capitalization stands at approximately $31.3 billion, indicating its significant presence in the healthcare industry [5] - The trading volume for Humana today is 1,073,203 shares, showcasing active investor interest [5] Analyst Insights - Erin Wright from Morgan Stanley set a price target of $262 for Humana, indicating a modest potential increase of 0.66% from the current stock price [2][6] - This price target reflects confidence in Humana's future performance, supported by recent developments [2] Government Contracts - The U.S. Defense Department awarded Humana a $7.3 billion contract, underscoring the company's strong position in the healthcare sector [3][6] - This deal involves providing healthcare and administrative support services, highlighting Humana's ongoing partnership with the Pentagon [3]

Core Viewpoint - Humana Inc. is a prominent health insurance provider in the U.S., recently rated "Underperform" by Morgan Stanley, which has lowered its price target for the company [1][6]. Financial Performance - Morgan Stanley adjusted Humana's price target from $277 to $262, while the stock was priced at $260.28, reflecting a slight increase of $2.12 or 0.82% [2][6]. - Humana's stock has fluctuated between $256.35 and $266.08 during the day, with a yearly high of $315.35 and a low of $206.87. The company's market capitalization is approximately $31.3 billion [4][6]. Contracts and Partnerships - The U.S. Defense Department awarded Humana a $7.3 billion contract for health care and administrative support services, indicating a strong relationship with the Pentagon and potential positive impacts on future financial performance [3][5][6]. Market Activity - Today's trading volume for Humana is 1,073,203 shares, indicating significant investor interest despite the "Underperform" rating from Morgan Stanley [5][6].

Key Takeaways CLOV is gaining share with 35% membership growth and nearly 50% revenue growth, backed by retention above 90%.CLOV sees higher margins as Clover Assistant drives profits and improves cost ratios for returning members.CLOV expands monetization through Counterpart Health, extending its platform beyond Medicare Advantage plans.Clover Health Investments (CLOV) is well poised for growth in the coming quarters, courtesy of its broad product spectrum. This optimism is primarily driven by its technolo ...

is House Minority Leader Hakee Jeff. Uh good morning to you. You heard the president uh last night.He says the Democrats are in the pockets of the insurance companies uh and that the price of uh your healthcare is actually going to go down under his plan. What say you. >> Well, good morning.Great to be with you. Uh the Republican health care crisis is devastating the American people and Donald Trump has zero credibility on the issue of healthcare. This is the party that has enacted the largest cut to Medica ...

About Cognizant: Cognizant (Nasdaq: CTSH) engineers' modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we're improving everyday life. See how at http://www.cognizant.com or @cognizant. HONG KONG, Dec. 17, 2025 /PRNewswire/ -- Cognizant (Nasdaq: CTSH) today announced a strategic collaboration with Bupa Hong Kong, a leading health insurance specialist in Hong Kong, to deliver Cognizant's first ...

The U.S. Defense Department on Wednesday said it was exercising an option to award Humana a $7.3 billion deal for health care and administrative support services. ...

BofA Securities flagged rising cost pressures, unpredictable swing factors and heightened uncertainty around earnings estimates for managed care organizations, noting that Medicare poses greater risk than Medicaid and that reported EPS may not fully reflect underlying earnings power. Despite limited near-term visibility, the firm sees meaningful long-term upside, arguing that most managed care organizations are currently earning below their true potential. • Cigna Group stock is holding steady today. What’s ...

UnitedHealth Group Incorporated (NYSE:UNH) is one of the stocks that Jim Cramer shared his take on. A caller asked if the stock was a trade for 2026 with a potential rebound or if it could be a long-term holding. In response, Cramer said: “Alright, I think that UnitedHealth has to be bought. I think that they’ve got a CEO who should come on the show. I think he’s doing everything right. Obviously, they had big, big problems, but you know what? This is UnitedHealth…. I’ve seen it come back from even an opt ...

Humana and the Nurses on Boards Coalition will leverage existing Humana's partnerships and NOBC's relationships with several universities around the country to recruit nursing students into the mentoring program. Details are still being finalized with the participating schools. To facilitate virtual mentoring, NOBC will implement a secure, scalable platform and other technologies needed to support the program: "A strong nursing workforce is vital to meeting the evolving healthcare needs of our communities – ...

Humana Inc.'s ( HUM ) stock dropped about 9% since I last checked in back in early October, from $284 to $258 per share. The price was jumpy, swinging up to $302 in October and falling to $221 inWith over 15 years of experience in the markets and a degree in economics, I focus on breaking down companies with clarity and discipline. My goal is to give individual investors a straightforward, honest view—what’s working, what isn’t, and where the risks and opportunities actually are. I don’t chase narratives. I ...